Results 51 to 60 of about 54,207 (313)

Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity. [PDF]

PLoS ONE, 2014
Dasatinib is a compound developed for chronic myeloid leukemia as a multi-targeted kinase inhibitor against wild-type BCR-ABL and SRC family kinases. Valproic acid (VPA) is an anti-epileptic drug that also acts as a class I histone deacetylase inhibitor.
Sook-Kyoung Heo, Eui-Kyu Noh, Dong-Joon Yoon, Jae-Cheol Jo, Jae-Hoo Park, Hawk Kim   +5 more
doaj   +1 more source

Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53 independent pathways [PDF]

, 2014
Most cancer cells use aerobic glycolysis to fuel their growth. The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer’s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD þ ) from reduced nicotinamide adenine
Allison, Simon J., Granchi, C., Knight, J.R.P., Milner, J., Minutolo, F., Phillips, R.M., Rani, R.   +6 more
core   +1 more source

Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma

BMC Cell Biology, 2018
Background Dasatinib (Sprycel) was developed as a tyrosine kinase inhibitor targeting Bcr-Abl and the family of Src kinases. Dasatinib is commonly used for the treatment of acute lymphoblastic and chronic myelogenous leukemia.
Josip Skoko, Jan Rožanc, Emilie M. Charles, Leonidas G. Alexopoulos, Markus Rehm   +4 more
doaj   +1 more source

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia

Respiratory Medicine Case Reports, 2022
Dasatinib, an effective second-generation tyrosine kinase inhibitor, is used to treat breakpoint cluster region-Ableson-positive chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia.
Go Makimoto, Mahito Misawa, Yoshinobu Maeda, Katsuyuki Kiura   +3 more
doaj  

Dasatinib: ten years of clinical practice worldwide

Онкогематология, 2016
The article contains results of meta-analysis of experience in use of second-generation tyrosine kinase inhibitors – dasatinib. The results of clinical trials dasatinib therapy in chronic myelogenous leukemia imatinib-resistant or intolerant patients are
K. M. Abdulkadyrov, V. A. Shuvaev, I. S. Martynkevich   +2 more
doaj   +1 more source

Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

Leukemia and Lymphoma, 2020
Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) is considered a feasible option, especially with the ability of second-generation tyrosine kinase inhibitors to induce higher rates of sustained deep ...
N. Shah, V. García‐Gutiérrez, A. Jiménez-Velasco, Sarah M. Larson, S. Saussele, D. Réa, F. Mahon, M. Levy, M. Gómez-Casares, F. Pane, F. Nicolini, M. Mauro, O. Sy, P. Martín-Regueira, J. Lipton   +14 more
semanticscholar   +1 more source

Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients

British Journal of Haematology, 2021
Dasatinib is a second‐generation BCR‐ABL1 tyrosine kinase inhibitor approved for patients with chronic myeloid leukaemia (CML). Dasatinib 100 mg per day is associated with an increased risk of pleural effusion (PlEff).
P. Rousselot, L. Mollica, J. Guilhot, A. Guerci, F. Nicolini, G. Étienne, L. Legros, A. Charbonnier, V. Coiteux, C. Dartigeas, M. Escoffre-barbe, L. Roy, P. Cony-Makhoul, V. Dubruille, M. Gardembas, F. Huguet, D. Réa, E. Cayssials, F. Guilhot, A. Bergeron, M. Molimard, F. Mahon, J. Cayuela, L. Busque, S. Bouchet   +24 more
semanticscholar   +1 more source

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. [PDF]

, 2013
PurposeDasatinib is a prototypic short half-life BCR-ABL1 tyrosine kinase inhibitor. The recommended dose of dasatinib for chronic myeloid leukemia in chronic phase was changed from 70 mg twice daily to 100 mg once daily following a Phase III dose ...
Chen, Tai-Tsang, Hochhaus, Andreas, Kantarjian, Hagop M, Roy, Amit, Shah, Neil P, Wang, Xiaoning   +5 more
core   +2 more sources

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

Journal of Clinical Oncology, 2016
PURPOSE We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and safety outcomes of patients with chronic myeloid leukemia ...
J. Cortes, G. Saglio, H. Kantarjian, M. Baccarani, J. Mayer, C. Boqué, N. Shah, C. Chuah, L. Casanova, Brigid Bradley-Garelik, G. Manos, A. Hochhaus   +11 more
semanticscholar   +1 more source

The impact of dasatinib on pregnancy outcomes [PDF]

American Journal of Hematology, 2015
Prolonged survival in patients with chronic myeloid leukemia treated with BCR‐ABL1‐targeted tyrosine kinase inhibitors allows consideration of parenthood for patients on chronic therapy, but there are limited data about the effects of dasatinib on pregnancy.
Ekaterina Chelysheva, Elisabetta Abruzzese, Jorge E. Cortes, Nicola Wallis, Jane F. Apperley, Mausumee Guha   +5 more
openaire   +3 more sources